Page 11 - எழுந்திரு காடு நிறுவனம் க்கு மீளுருவாக்கம் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: AlphaMed Press Durham, NC - A phase 2 clinical trial whose results were released today in STEM CELLS Translational Medicine might point to a way to overcome bronchopulmonary dysplasia (BPD), a major cause of death in preterm infants. The study, conducted by researchers at Samsung Medical Center, Sungkyunkwan University and Asan Medical Center Children s Hospital in Seoul, evaluates the effectiveness of treating these infants by transplanting umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) directly into their tracheas. Early results showed signs of improvement for the most immature infants included in the trial. BPD is a serious breathing disorder in which the lungs do not develop normally. Most infants who develop BPD are born more than 10 weeks before their due date, weigh less than 2 pounds at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to the disorder. Despite recent advances in neonatal m

Soult ukpyolsiSouth koreaUnited kingdomNorthern irelandSan franciscoUnited statesAnthony atalaRegenerative medicine foundationAsan medical center children hospitalSungkyunkwan universityUniversity of ulsanSamsung medical centerSungkyunkwan university school of medicineWake forest institute for regenerative medicineAsan medical center childrenSoon park